Jasper Therapeutics reports positive updated data from Briquilimab studies in Chronic Spontaneous Urticaria (CSU). The data shows significant efficacy in controlling the disease with minimal adverse events.
BEACON study participants achieved high response rates at 12 weeks. Open label extension study also demonstrated strong efficacy with 58% of CSU participants achieving complete response at 12 weeks.
The results support the advancement of briquilimab and pave the way for the upcoming Phase 2b study in CSU planned for the second half of 2026.
High Response Rates
67% of BEACON study participants achieved complete response at 12 weeks with a mean UAS7 reduction of 31 points.
Efficacy in Open Label Study
58% of CSU participants in the open label extension study achieved complete response at 12 weeks.
Safety Profile
Briquilimab demonstrated favorable safety and tolerability profiles in both BEACON and open label extension studies.
Study Design
BEACON study evaluates multiple ascending doses of subcutaneous briquilimab for adult patients with CSU. Open label extension study includes patients with CSU and CIndU on a Q8W dosing schedule.
- The positive data from the BEACON and open label extension studies indicate a promising future for briquilimab in treating CSU and related conditions.
- The low frequency of adverse events and the high response rates observed suggest that briquilimab could offer a differentiated profile in chronic urticaria treatment.
The updated data from Jasper Therapeutics reinforces the potential of briquilimab as a novel therapy for Chronic Spontaneous Urticaria. The encouraging results support further development and evaluation of briquilimab in upcoming studies.